SCHEMBL24189784

SCHEMBL24189784

COC(=O)c1cc2c(S(C)(=O)=O)cccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.46
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
KIF11 P52732 1/20 0.43
GAA P10253 2/20 0.43
CYP1A2 P05177 2/20 0.43
GLA P06280 1/20 0.43
ULK1 O75385 1/20 0.42
FLT3 P36888 1/20 0.42
XDH P47989 1/20 0.42
MAPT P10636 2/20 0.41
IDO1 P14902 1/20 0.40
PTPN1 P18031 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
PDE5A O76074 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24190029 0.84 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL29015652 0.81 FLT3 (0.49) NR4A2KDM4EALDH1A1HSD17B10MEN1
SCHEMBL30397530 0.79 KDM4E (0.46) NR4A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL915460 0.79 HRH4 (0.55) NR4A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30310659 0.79 HRH4 (0.55) NR4A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2134591 0.79 FLT3 (0.58) NR4A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL8655451 0.78 HRH4 (0.56) NR4A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2323348 0.78 FLT3 (0.59) NR4A2KIF11GAACYP1A2GLA
SCHEMBL2205092 0.78 HRH4 (0.56) NR4A2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL217459 0.78 FLT3 (0.66) KDM4EMEN1KMT2AGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 CN disclosed
EP-4165037-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Aligos Therapeutics, Inc. (US) 2023-04-19 EP disclosed
US-20220009903-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-01-13 US disclosed
US-20220009903-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 NR4A2 3319/4885KDM4E 3205/4885ALDH1A1 2039/4885
US-20220009903-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 NR4A2 3319/4885KDM4E 3205/4885ALDH1A1 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.